GlassScriptPhysician profile
Vasco M Marques
NPI 1588730113
$41,283.09
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,279 · 2021: $810 · 2022: $1,596 · 2023: $19K · 2024: $21.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $1,994 · Travel and Lodging: $1,634 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,000.00 |
| Food and Beverage | $1,993.85 |
| Travel and Lodging | $1,634.13 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17,571.88 | 2022-2023 | Venaseal, Closurefast |
| Medtronic Vascular, INC. | $15,787.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $987.47 | 2019-2023 | Jardiance |
| Biotronik INC. | $721.71 | 2019-2022 | |
| Abbott Laboratories | $571.67 | 2019-2023 | Mitraclip, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $376.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $359.80 | 2019-2023 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $341.63 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $335.14 | 2019-2021 | |
| Vital Connect, INC | $279.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.36 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.02 | 2019-2023 | Lifevest |
| Lundbeck LLC | $253.24 | 2019-2021 | |
| Amgen INC. | $245.96 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $217.30 | 2020-2023 | Opsumit, Uptravi |
Show all 54 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasco Marques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.